CANCER DISCOVERY CONTENTS

JULY 2024 ▪ VOLUME 14 ▪ NUMBER 7



















CANCER DISCOVERY

CONTENTS

ON THE COVER The majority of antitumor therapeutic strategies inhibit aberrant oncogenic pathways. As an alternative approach, Dias and colleagues assessed the efficacy of paradoxical hyperactivation of oncogenic signaling in disrupting cancer homeostasis and suppressing tumor growth. Inhibition of protein phosphatase 2A (PP2A) led to overactivation of several oncogenic signaling pathways and subsequent induction of stress responses in colon cancer cells. Combined inhibition of PP2A and WEE1 synergistically suppressed tumor growth in multiple models as well as patient-derived tumors. Notably, resistance to this therapeutic combination was tumor suppressive, resulting in loss of oncogenic signaling and inhibition of tumor growth *in vivo*. These findings support further clinical evaluation of deliberate hyperactivation of oncogenic signaling as a potential anticancer therapeutic strategy. For more information, see the article by Dias and colleagues on page 1276. Artwork by Bianca Dunn.

doi: 10.1158/2159-8290.CD-14-7-CVR



NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of BavencioR (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to https://aacrjournals. org/pages/editorial-policies#coi.